Contents

20 June 2018
Vol 10, Issue 446

About The Cover

Cover image expansion

ONLINE COVER Breathing New Life into Kinase Inhibitors. Mutations in signaling pathways can allow lung cells to become cancerous, eventually leading to the formation of lung tumors like the one pictured here. KRAS mutations drive the growth of many lung cancers and typically have been thought to be resistant to EGFR tyrosine kinase inhibition. Two groups (Moll et al. and Kruspig et al.) have independently reassessed this notion using patient samples and mouse models. They uncovered the mechanisms responsible for KRAS-mutation resistance to kinase inhibition and show how combination treatment targeting EGFR and other kinases could effectively target this common subset of lung cancers. [CREDIT: MOREDUN ANIMAL HEALTH LTD/SCIENCE SOURCE]